Value of platelet-albumin-bilirubin index combined with AIMS65 score in predicting the short-term prognosis of patients with liver cirrhosis and acute upper gastrointestinal bleeding
Objective To investigate the value of platelet-albumin-bilirubin index (PALBI) combined with AIMS65 score in predicting rebleeding and death within 6 weeks after admission in patients with liver cirrhosis and acute upper gastrointestinal bleeding (AUGIB).Methods A retrospective study was conducted for 238 patients with liver cirrhosis and AUGIB who were hospitalized in The First Affiliated Hospital of Jinzhou Medical University from February 2021 to October 2022, and all patients were followed up for 6 weeks. According to the prognosis, they were divided into death group with 65 patients and survival group with 173 patients, and according to the presence or absence of rebleeding, they were divided into non-rebleeding group with 149 patients and rebleeding group with 89 patients. General data and laboratory markers (including blood routine, liver/renal function, and coagulation), and PALBI, AIMS65 score, Child-Turcotte-Pugh (CTP) score, and Model for End-stage Liver Disease (MELD) score were calculated on admission. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. A multivariate logistic regression model analysis was used to investigate the risk factors for death or rebleeding within 6 weeks after admission in patients with liver cirrhosis and AUGIB. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to investigate the predictive efficacy of each scoring system, and the DeLong test was used for comparison of AUC.Results There were significant differences between the death group and the survival group in hematemesis, past history of varices, albumin (Alb), total bilirubin (TBil), international normalized ratio (INR), creatinine (Cr), prothrombin time (PT), systolic blood pressure, PALBI, AIMS65 score, CTP score, and MELD score (all P<0.05). The multivariate logistic regression analysis showed that hematemesis (odds ratio [OR]=4.34, 95% confidence interval [CI]: 1.88 — 10.05, P<0.001), past history of varices (OR=3.51, 95%CI: 1.37 — 8.98, P=0.009), PALBI (OR=4.49, 95%CI: 1.48 — 13.64, P=0.008), and AIMS65 score (OR=3.85, 95%CI: 2.35 — 6.30, P<0.001) were independent risk factors for death. The ROC curve analysis of each scoring system in predicting survival showed that CTP score, MELD score, PALBI, AIMS65 score, and PALBI combined with AIMS65 score had an AUC of 0.758, 0.798, 0.789, 0.870, and 0.888, respectively, suggesting that PALBI combined with AIMS65 score had a significantly larger AUC than the four scoring systems used alone (all P<0.05). There were significant differences between the rebleeding group and the non-rebleeding group in hematemesis, history of diabetes, Alb, TBil, INR, Cr, PT, PALBI, AIMS65 score, CTP score, and MELD score (all P<0.05). The multivariate logistic regression analysis showed that PALBI (OR=2.41, 95%CI: 1.17 — 4.95, P=0.017) and AIMS65 score (OR=1.58, 95%CI: 1.17 — 2.15, P=0.003) were independent risk factors for rebleeding. The ROC curve analysis of each scoring system in predicting rebleeding showed that CTP score, MELD score, PALBI, AIMS65 score, and PALBI combined with AIMS65 score had an AUC of 0.680, 0.719, 0.709, 0.711, and 0.741, respectively, suggesting that PALBI combined with AIMS65 score had the largest AUC (all P<0.05), but with a relatively low specificity.Conclusion PALBI combined with AIMS65 score has a certain value in predicting death within 6 weeks after admission in patients with liver cirrhosis and AUGIB, with a better value than CTP score and MELD score alone. PALBI combined with AIMS65 score has a relatively low value in predicting rebleeding within 6 weeks, with an acceptable accuracy.
Figure
8.
Unidimensional statistical analysis of intestinal differential metabolices before and after treatment with Yiqi Yangyin Jiedu Huayu prescription
Figure
9.
Multidimensional statistical analysis of intestinal differential metabolites before and after treatment with Yiqi Yangyin Jiedu Huayu prescription
ZHANG K, LIU JL, LIU YL, et al. Clinical effect of transjugular intrahepatic portosystemic shunt guided by the three-dimensional model constructed using thin-slice CT scan data in treatment of cirrhotic portal hypertension with gastrointestinal bleeding[J]. Clin J Med Offic, 2023, 51( 6): 655- 656, 660. DOI: 10.16680/j.1671-3826.2023.06.28.
JAKAB SS, GARCIA-TSAO G. Evaluation and management of esophageal and gastric varices in patients with cirrhosis[J]. Clin Liver Dis, 2020, 24( 3): 335- 350. DOI: 10.1016/j.cld.2020.04.011.
[5]
Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
OIKONOMOU T, GOULIS L, DOUMTSIS P, et al. ALBI and PALBI grades are associated with the outcome of patients with stable decompensated cirrhosis[J]. Ann Hepatol, 2019, 18( 1): 126- 136. DOI: 10.5604/01.3001.0012.7904.
[7]
ROBERTSON M, NG J, SHAWISH W ABU, et al. Risk stratification in acute variceal bleeding: Comparison of the AIMS65 score to established upper gastrointestinal bleeding and liver disease severity risk stratification scoring systems in predicting mortality and rebleeding[J]. Dig Endosc, 2020, 32( 5): 761- 768. DOI: 10.1111/den.13577.
[8]
FREEMAN R. The new liver allocation system: Moving toward evidence-based transplantation policy[J]. Liver Transplant, 2002, 8( 9): 851- 858. DOI: 10.1053/jlts.2002.35927.
[9]
CHILD CG, TURCOTTE JG. Surgery and portal hypertension[J]. Major Probl Clin Surg, 1964, 1: 1- 85.
[10]
GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65( 1): 310- 335. DOI: 10.1002/hep.28906.
[11]
Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension(2019 edition)[J]. Chin J Pract Surg, 2019, 39( 12): 1241- 1247. DOI: 10.19538/j.cjps.issn1005-2208.2019.12.01.
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32( 2): 203- 219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
Chinese Society of Hepatology, Chinese Society of Gastroenterology, and Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538.
TANDON P, BISHAY K, FISHER S, et al. Comparison of clinical outcomes between variceal and non-variceal gastrointestinal bleeding in patients with cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33( 10): 1773- 1779. DOI: 10.1111/jgh.14147.
[15]
LANAS A, DUMONCEAU JM, HUNT RH, et al. Non-variceal upper gastrointestinal bleeding[J]. Nat Rev Dis Primers, 2018, 4: 18020. DOI: 10.1038/nrdp.2018.20.
[16]
LI YY, LI HY, ZHU Q, et al. Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: Hematemesis versus melena without hematemesis[J]. Eur J Gastroenterol Hepatol, 2019, 31( 11): 1334- 1341. DOI: 10.1097/MEG.0000000000001524.
[17]
MANDAL AK, PAUDEL MS, KC S, et al. Factors predicting mortality of acute variceal bleeding in liver cirrhosis[J]. JNMA J Nepal Med Assoc, 2018, 56( 209): 493- 496.
[18]
GARCIA-TSAO G, BOSCH J. Varices and variceal hemorrhage in cirrhosis: A new view of an old problem[J]. Clin Gastroenterol Hepatol, 2015, 13( 12): 2109- 2117. DOI: 10.1016/j.cgh.2015.07.012.
[19]
ROAYAIE S, JIBARA G, BERHANE S, et al. 851 PALBI-An objective score based on platelets, albumin bilirubin stratifies HCC patients undergoing resection& ablation better than Child’s classification[J]. Hepatology, 2015, 62: 624- 690.
[20]
ELSHAARAWY O, ALLAM N, ABDELSAMEEA E, et al. Platelet-albumin-bilirubin score- a predictor of outcome of acute variceal bleeding in patients with cirrhosis[J]. World J Hepatol, 2020, 12( 3): 99- 107. DOI: 10.4254/wjh.v12.i3.99.
JIANG TT, ZHANG Q, WANG XB, et al. Effect of Yiqi Yangyin Jiedu Huayu prescription on intestinal metabolites in liver cirrhosis with minimal hepatic encephalopathy: A study based on metabolomics[J]. J Clin Hepatol, 2025, 41(3): 469-477. DOI: 10.12449/JCH250312.
JIANG TT, ZHANG Q, WANG XB, et al. Effect of Yiqi Yangyin Jiedu Huayu prescription on intestinal metabolites in liver cirrhosis with minimal hepatic encephalopathy: A study based on metabolomics[J]. J Clin Hepatol, 2025, 41(3): 469-477. DOI: 10.12449/JCH250312.